JP2016512223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512223A5 JP2016512223A5 JP2015562400A JP2015562400A JP2016512223A5 JP 2016512223 A5 JP2016512223 A5 JP 2016512223A5 JP 2015562400 A JP2015562400 A JP 2015562400A JP 2015562400 A JP2015562400 A JP 2015562400A JP 2016512223 A5 JP2016512223 A5 JP 2016512223A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- cdr
- acid sequence
- isolated antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 47
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 claims description 17
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 claims description 17
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 claims description 16
- 239000010445 mica Substances 0.000 claims description 15
- 229910052618 mica group Inorganic materials 0.000 claims description 15
- 125000000539 amino acid group Chemical group 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 4
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000009033 hematopoietic malignancy Effects 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241001251094 Formica Species 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801329P | 2013-03-15 | 2013-03-15 | |
| US61/801,329 | 2013-03-15 | ||
| US201461940372P | 2014-02-15 | 2014-02-15 | |
| US61/940,372 | 2014-02-15 | ||
| PCT/IB2014/001157 WO2014140904A2 (en) | 2013-03-15 | 2014-03-15 | Antibodies to mica and micb proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019080239A Division JP2019194180A (ja) | 2013-03-15 | 2019-04-19 | Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2016512223A JP2016512223A (ja) | 2016-04-25 |
| JP2016512223A5 true JP2016512223A5 (enExample) | 2017-04-20 |
| JP6518199B2 JP6518199B2 (ja) | 2019-05-22 |
| JP6518199B6 JP6518199B6 (ja) | 2019-06-12 |
Family
ID=51538216
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562400A Expired - Fee Related JP6518199B6 (ja) | 2013-03-15 | 2014-03-15 | Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体 |
| JP2019080239A Pending JP2019194180A (ja) | 2013-03-15 | 2019-04-19 | Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019080239A Pending JP2019194180A (ja) | 2013-03-15 | 2019-04-19 | Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10851148B2 (enExample) |
| EP (1) | EP2970490A4 (enExample) |
| JP (2) | JP6518199B6 (enExample) |
| AU (1) | AU2014229476B2 (enExample) |
| CA (1) | CA2906356A1 (enExample) |
| WO (1) | WO2014140904A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2257301B1 (en) | 2008-03-03 | 2014-01-22 | The University of Miami | Allogeneic cancer cell-based immunotherapy |
| EP3145953A1 (en) * | 2014-05-21 | 2017-03-29 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer with anti bip or anti mica antibodies |
| MY181834A (en) | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| KR20170109582A (ko) | 2015-02-06 | 2017-09-29 | 히트 바이오로직스, 인코퍼레이티드 | 벡터 공동 발현 백신 및 공동 자극 분자 |
| CN108770343A (zh) * | 2015-12-04 | 2018-11-06 | 达纳－法伯癌症研究所公司 | 用于治疗癌症的使用MICA/Bα3结构域的疫苗接种 |
| CA3040123A1 (en) | 2016-10-11 | 2018-04-19 | University Of Miami | Vectors and vaccine cells for immunity against zika virus |
| CN110088137A (zh) * | 2016-10-19 | 2019-08-02 | 诺瓦罗技科斯生物科技有限公司 | 针对mica和micb蛋白的抗体 |
| CN107964041B (zh) * | 2016-10-20 | 2023-08-01 | 中国科学院广州生物医药与健康研究院 | 高稳定性和高亲和力的dmic及其制法 |
| US11555076B2 (en) * | 2016-10-29 | 2023-01-17 | Genentech, Inc. | Anti-MIC antibodies and methods of use |
| CN108204958A (zh) * | 2016-12-19 | 2018-06-26 | 伊缪泰普有限公司 | 结合测定 |
| WO2018141959A1 (en) | 2017-02-06 | 2018-08-09 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
| US11548930B2 (en) | 2017-04-04 | 2023-01-10 | Heat Biologics, Inc. | Intratumoral vaccination |
| EP3743109A4 (en) * | 2018-01-25 | 2021-11-10 | Cullinan Mica Corp. | MICA / B ANTIBODIES AND METHOD OF USE |
| CA3093407A1 (en) | 2018-03-23 | 2019-09-26 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| AU2019284911B2 (en) | 2018-06-13 | 2026-04-09 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
| EP3830128A4 (en) * | 2018-07-31 | 2022-08-17 | Cullinan Mica Corp. | ANTI-MICA/B ANTIBODIES THAT BLOCK MICA/B-SHEDDING AND METHODS OF USE |
| WO2020035345A1 (en) | 2018-08-14 | 2020-02-20 | Innate Pharma | Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody |
| AU2019408408A1 (en) | 2018-12-21 | 2021-06-03 | Valerio Therapeutics | New conjugated nucleic acid molecules and their uses |
| US12404331B2 (en) | 2019-04-19 | 2025-09-02 | Tcrcure Biopharma Corp. | Anti-PD-1 antibodies and uses thereof |
| WO2021041238A1 (en) * | 2019-08-23 | 2021-03-04 | Northwestern University | Materials and methods for activating antigen-specific t cell responses |
| AR122644A1 (es) | 2020-06-19 | 2022-09-28 | Onxeo | Nuevas moléculas de ácido nucleico conjugado y sus usos |
| CN116547301A (zh) * | 2020-08-10 | 2023-08-04 | 先天制药公司 | 使用抗体进行的细胞表面mica和micb检测 |
| CN112574311B (zh) * | 2020-12-14 | 2022-03-25 | 广州康盛生物科技股份有限公司 | 双mic结合活性的抗体及其应用 |
| US20240216554A1 (en) * | 2021-05-04 | 2024-07-04 | Actinium Pharmaceuticals, Inc. | Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancer |
| AU2022409713A1 (en) | 2021-12-16 | 2024-06-20 | Valerio Therapeutics | New conjugated nucleic acid molecules and their uses |
| JP2025512137A (ja) * | 2022-04-08 | 2025-04-16 | ディーツーエム バイオセラピューティクス リミテッド | 抗ｍｉｃａ／ｂ抗体及びその使用 |
| KR102783449B1 (ko) * | 2022-06-15 | 2025-03-19 | 주식회사 셀리드 | 자연 살해 ｔ 세포의 리간드와 암 항원을 적재한 자연 살해 세포를 포함하는 백신 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2275141A1 (en) | 1996-10-29 | 1998-05-07 | Thomas Spies | Cell stress regulated human mhc class i gene |
| ATE434624T1 (de) | 2001-10-04 | 2009-07-15 | Immunex Corp | Ul16-bindungsprotein 4 |
| CA2483343A1 (en) * | 2002-04-22 | 2003-10-30 | Fred Hutchinson Cancer Research Center | Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions |
| US7666417B2 (en) | 2003-04-22 | 2010-02-23 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating autoimmune diseases or conditions |
| JP2008511340A (ja) | 2004-04-30 | 2008-04-17 | バイオフェレシス テクノロジーズ， インコーポレイテッド | 患者において可溶性ｔｎｆｒ１、可溶性ｔｎｆｒ２、および可溶性ｉｌ２を除去する方法およびシステム |
| DE102004042894A1 (de) | 2004-08-30 | 2006-03-02 | Eberhard-Karls-Universität Tübingen | Verwendung von Blockern der NKG2D-Rezeptor-/NKG2D-Liganden-Interaktion bei Autoimmunerkrankungen |
| CA2665090A1 (en) | 2006-09-22 | 2008-03-27 | Dana-Farber Cancer Institute, Inc. | Methods for treating mica-related disorders |
| CA3011859A1 (en) | 2007-04-23 | 2008-10-30 | Fred Hutchinson Cancer Research Center | Negative immunomodulation of immune responses by erp5 |
| US8182809B1 (en) * | 2008-09-08 | 2012-05-22 | University Of Washington | Methods for treating cancer by inhibiting MIC shedding |
| WO2010080124A2 (en) | 2008-12-18 | 2010-07-15 | Dana-Farber Cancer Institute, Inc. | Nkg2d-fc for immunotherapy |
| US8796420B2 (en) | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
| TWI408370B (zh) | 2011-05-19 | 2013-09-11 | 長庚大學 | 胰臟癌之血清生物檢測標誌及其應用 |
| US8753640B2 (en) * | 2011-05-31 | 2014-06-17 | University Of Washington Through Its Center For Commercialization | MIC-binding antibodies and methods of use thereof |
| PT2760471T (pt) | 2011-09-30 | 2017-03-22 | Dana Farber Cancer Inst Inc | Péptidos terapêuticos |
| WO2013117647A1 (en) | 2012-02-07 | 2013-08-15 | Innate Pharma | Mica binding agents |
| EP2626994B1 (en) | 2012-02-08 | 2019-04-03 | GE Oil & Gas UK Limited | Supplying electrical power to subsea equipment |
| US20160030659A1 (en) | 2013-03-15 | 2016-02-04 | Novelogics Biotechnology, Inc. | Methods and devices for removal of immunosuppressive ligands |
-
2014
- 2014-03-15 US US14/776,640 patent/US10851148B2/en not_active Expired - Fee Related
- 2014-03-15 CA CA2906356A patent/CA2906356A1/en not_active Abandoned
- 2014-03-15 AU AU2014229476A patent/AU2014229476B2/en not_active Ceased
- 2014-03-15 JP JP2015562400A patent/JP6518199B6/ja not_active Expired - Fee Related
- 2014-03-15 EP EP14762844.0A patent/EP2970490A4/en not_active Withdrawn
- 2014-03-15 WO PCT/IB2014/001157 patent/WO2014140904A2/en not_active Ceased
-
2019
- 2019-04-19 JP JP2019080239A patent/JP2019194180A/ja active Pending
-
2020
- 2020-07-14 US US16/928,977 patent/US20210040173A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503380A5 (enExample) | ||
| JP2022515318A5 (enExample) | ||
| JP2018524394A5 (enExample) | ||
| JP2021514664A5 (enExample) | ||
| JP2017149720A5 (enExample) | ||
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| RU2014106671A (ru) | Варианты гуманизированных иммуномодулирующих моноклональных антител | |
| JP2020501531A5 (enExample) | ||
| JP2018520650A5 (enExample) | ||
| JP2018513149A5 (enExample) | ||
| JP2014530215A5 (enExample) | ||
| JP2021531764A5 (enExample) | ||
| JP2015506912A5 (enExample) | ||
| JP2019535763A5 (enExample) | ||
| JP2017501167A5 (enExample) | ||
| JP2016521692A5 (enExample) | ||
| JP2015534577A5 (enExample) | ||
| JP2016529215A5 (enExample) | ||
| JP2015508280A5 (enExample) | ||
| JP2020514310A5 (enExample) | ||
| JP2016526904A5 (enExample) | ||
| JP2018517431A5 (enExample) | ||
| JP2019531764A5 (enExample) | ||
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2020502271A5 (enExample) |